Skip to main content

Table 2 Slope, intercept, Pearson correlation coefficient, and predicted LDL-C and non-HDL-C values based on simple linear regression of LDL-C or non-HDL-C on apoB at baseline (i.e., prior to receiving randomized treatment) and Week 12

From: Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

Treatment Group Na Slope Intercept apoB vs LDL-C
Pearson Correlation Coefficient (95 % CI) [R2]
Predictedb
LDL-C Value (95 % CI) given apoB of 0.8 g/L
Predictedb
LDL-C Value (95 % CI) given apoB of 0.9 g/L
Baseline (i.e., pre-treatment measurement)
 Pooled across treatment groups 721 2.04 0.36 0.72 (069, 0.76) [0.53] 1.98 (1.95, 2.01) 2.18 (2.16, 2.21)
 TG <2.26 mmol/L 602 2.35 0.13 0.77 (0.74, 0.80) [0.59] 2.01 (1.98, 2.04) 2.24 (2.22, 2.27)
 TG ≥2.26 mmol/L 119 2.35 −0.27 0.78 (0.70, 0.84) [0.61] 1.61 (1.50, 1.73) 1.85 (1.76, 1.93)
 ERN/LRPT 395 2.04 0.35 0.73 (0.68, 0.77) [0.53] 1.99 (1.94, 2.03) 2.19 (2.15, 2.23)
 TG <2.26 mmol/L 322 2.43 0.07 0.80 (0.75, 0.83) [0.64] 2.02 (1.98, 2.06) 2.26 (2.23, 2.30)
 TG ≥2.26 mmol/L 73 2.22 −0.16 0.74 (0.61, 0.83) [0.55] 1.63 (1.47, 1.79) 1.85 (1.73, 1.98)
 Placebo 326 1.99 0.38 0.72 (0.66, 0.76) [0.51] 1.98 (1.93, 2.02) 2.18 (2.14, 2.21)
 TG <2.26 mmol/L 280 2.20 0.23 0.72 (0.66, 0.78) [0.53] 2.00 (1.96, 2.04) 2.22 (2.18, 2.26)
 TG ≥2.26 mmol/L 46 2.51 −0.41 0.85 (0.73, 0.91) [0.72] 1.59 (1.43, 1.75) 1.84 (1.71, 1.97)
Week 12
 ERN/LRPT 394 2.30 0.04 0.82 (0.79, 0.85) [0.68] 1.88 (1.84, 1.91) 2.11 (2.07, 2.15)
 TG <2.26 mmol/L 321 2.61 −0.16 0.84 (0.80, 0.87) [0.70] 1.93 (1.90, 1.97) 2.20 (2.15, 2.24)
 TG ≥2.26 mmol/L 73 1.99 0.13 0.86 (0.78, 0.91) [0.74] 1.73 (1.65, 1.81) 1.93 (1.86, 2.00)
 Placebo 323 2.09 0.27 0.73 (0.68, 0.78) [0.54] 1.94 (1.89, 1.98) 2.14 (2.07, 2.15)
 TG <2.26 mmol/L 279 2.35 0.06 0.77 (0.71, 0.81) [0.59] 1.94 (1.89, 1.98) 2.17 (2.13, 2.21)
 TG ≥2.26 mmol/L 44 1.68 0.50 0.69 (0.49, 0.82) [0.47] 1.84 (1.66, 2.02) 2.01 (1.86, 2.15)
Treatment Group Na Slope Intercept apoB vs non-HDL-C
Pearson Correlation Coefficient (95 % CI) [R2]
Predictedb
Non-HDL-C Value (95 % CI) given apoB of 0.8 g/L
Predictedb
Non-HDL-C Value (95 % CI) given apoB of 0.9 g/L
Baseline (i.e., pre-treatment measurement)
 Pooled across treatment groups 721 2.97 0.21 0.87 (0.85, 0.89) [0.76] 2.59 (2.56, 2.62) 2.89 (2.87, 2.91)
 TG <2.26 mmol/L 602 2.82 0.31 0.84 (0.82, 0.87) [0.71] 2.57 (2.54, 2.60) 2.85 (2.83, 2.88)
 TG ≥2.26 mmol/L 119 2.59 0.81 0.85 (0.79, 0.89) [0.72] 2.88 (2.78, 2.98) 3.14 (3.06, 3.21)
 ERN/LRPT 395 2.95 0.25 0.87 (0.85, 0.89) [0.76] 2.61 (2.57, 2.65) 2.90 (2.87, 2.94)
 TG <2.26 mmol/L 322 2.82 0.32 0.86 (0.83, 0.89) [0.74] 2.58 (2.54, 2.61) 2.86 (2.83, 2.89)
 TG ≥2.26 mmol/L 73 2.38 1.07 0.81 (0.71, 0.87) [0.65] 2.97 (2.83, 3.10) 3.20 (3.10, 3.31)
 Placebo 326 3.00 0.17 0.87 (0.84, 0.89) [0.75] 2.57 (2.53, 2.61) 2.87(2.84, 2.90)
 TG <2.26 mmol/L 280 2.82 0.30 0.82 (0.78, 0.86) [0.67] 2.56 (2.52, 2.60) 2.84 (2.81, 2.88)
 TG ≥2.26 mmol/L 46 2.87 0.46 0.91 (0.83, 0.95) [0.82] 2.76 (2.62, 2.90) 3.05 (2.94, 3.15)
Week 12
 ERN/LRPT 394 3.28 -0.13 0.89 (0.87, 0.91) [0.79] 2.49 (2.45, 2.53) 2.82 (2.78, 2.86)
 TG <2.26 mmol/L 321 3.15 -0.06 0.87 (0.84, 0.90) [0.76] 2.47 (2.43, 2.51) 2.78 (2.74, 2.83)
 TG ≥2.26 mmol/L 73 3.36 -0.12 0.88 (0.82, 0.92) [0.78] 2.56 (2.44, 2.68) 2.89 (2.78, 3.00)
 Placebo 323 3.21 -0.04 0.87 (0.84, 0.90) [0.76] 2.52 (2.48, 2.56) 2.84 (2.80, 2.88)
 TG <2.26 mmol/L 279 3.00 0.12 0.85 (0.82, 0.88) [0.73] 2.52 (2.48, 2.57) 2.82 (2.79, 2.86)
 TG ≥2.26 mmol/L 44 3.60 -0.33 0.89 (0.79, 0.93) [0.78] 2.55 (2.35, 2.75) 2.91 (2.75, 3.07)
  1. apoB apolipoprotein B; LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; ERN/LRPT niacin/lariproprant; TG triglyceride
  2. aNumber of patients with paired apoB and LDL-C or non-HDL-C measurements
  3. bPredicted LDL-C or non-HDL-C value (mmol/L) assuming apoB value of 0.8 or 0.9 g/L